Revolution Medicines (RVMD) Change in Accured Expenses (2019 - 2026)

Revolution Medicines has reported Change in Accured Expenses for 8 years, with the latest figure at $55.8 million in Q2 2026.

• On a quarterly basis, Change in Accured Expenses rose 415.55% year-over-year to $55.8 million in Q2 2026; TTM through Jun 2026 was $138.9 million, a 239.31% increase from a year earlier, with the FY2025 full-year figure at $112.3 million, up 410.65% from the prior year.
• Change in Accured Expenses was $55.8 million for Q2 2026 at Revolution Medicines, up from -$16.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $55.8 million in Q2 2026, with the low at -$21.3 million in Q1 2024.
• Average Change in Accured Expenses over 5 years is $10.5 million, with a median of $7.7 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2026: Change in Accured Expenses surged 685.1% in 2023, then tumbled 1180.63% in 2026.
• Over 5 years, Change in Accured Expenses stood at -$3.0 million in 2022, then sank by 112.1% to -$6.3 million in 2023, then jumped by 390.86% to $18.3 million in 2024, then jumped by 198.42% to $54.6 million in 2025, then increased by 2.16% to $55.8 million in 2026.
• The last three Change in Accured Expenses figures came in at $55.8 million (Q2 2026), -$16.7 million (Q1 2026), and $54.6 million (Q4 2025), per Business Quant data.